Loading clinical trials...
Loading clinical trials...
A Phase 1/2, Open-Label, Multicenter Study of ACY-1215 (Ricolinostat) in Combination With Lenalidomide and Dexamethasone for the Treatment of Relapsed or Relapsed/Refractory Multiple Myeloma
Conditions
Interventions
ACY-1215
lenalidomide
+1 more
Locations
5
United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
University of North Carolina
Chapel Hill, North Carolina, United States
Sarah Cannon Research Institute Drug Development Unit
Nashville, Tennessee, United States
Fred Hutchinson Cancer Research Center
Seattle, Washington, United States
Start Date
July 12, 2012
Primary Completion Date
March 15, 2021
Completion Date
March 24, 2021
Last Updated
February 23, 2022
NCT06152575
NCT06179888
NCT04973605
NCT05201781
NCT05862012
NCT06138275
Lead Sponsor
Celgene
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions